Resistance of colorectal cancer cells to 5-FUdR and 5-FU caused by mycoplasma infection

被引:1
|
作者
Jettte, Lucie [1 ]
Bissoon-Haqqani, Seema [1 ,3 ]
Le Francois, Brice [1 ,3 ]
Maroun, Jean A. [2 ]
Birnboim, H. Chaim [1 ,3 ]
机构
[1] Ottawa Hlth Res Inst, Ctr Canc Therapeut, Ottawa, ON K1H 8L6, Canada
[2] Ottawa Reg Canc Ctr, Ottawa, ON K1Y 4K7, Canada
[3] Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1N 6N5, Canada
关键词
thymidylate synthase; resistance; 5-FU; 5-FUdR; mycoplasma;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: 5-Fluorouracil (5-FU) is an antineoplastic drug that targets thymidylate synthase (TS). Tumour cells can develop resistance to anti-TS drugs by a variety of mechanisms including up-regulation of TS protein and alterations in drug uptake and degradation. The possible mechanisms of the observed rapid development of resistance to the pyrimidine analogs 5-FUdR and 5-FU in cultured HCT116 colon cancer cells were investigated. Materials and Methods: Cell survival was determined in resistant and control HCT116 cells treated with 5-FUdR and 5-FU for 7 days. The ability of the cells to take up and metabolize these drugs was determined by Western blotting and [H-3]thymidine incorporation. Results and Conclusion: Resistant HCT116 cells were 5- and 100-fold more resistant to killing by 5-FU and 5-FUdR, respectively, than the parental cells and exhibited impaired uptake. Although the HCT116R cells were initially Mycoplasma free, a low level of Mycoplasma contamination was found in these cells after several weeks in culture. Sensitivity to 5-FUdR was restored by treatment with an anti-Mycoplasma antibiotic. Our observations emphasize the need for frequent testing for Mycoplasma contamination in any cell line under investigation for resistance to anti-TS drugs.
引用
收藏
页码:2175 / 2180
页数:6
相关论文
共 50 条
  • [21] Combined radiation therapy and chemotherapy - 5-FU and FUdR - Introduction
    Lawrence, TS
    Tepper, JE
    SEMINARS IN RADIATION ONCOLOGY, 1997, 7 (04) : 247 - 248
  • [22] Adjuvant 5-FU based therapy for colorectal cancer
    Muñoz, A
    Rubio, I
    Mañé, JM
    Barceló, JR
    Fernández, R
    Abón, G
    Fuente, N
    López-Vivanco, G
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S78 - S78
  • [23] NEW 5-FU MODIFICATIONS IN COLORECTAL-CANCER
    EINHORN, LH
    CANCER INVESTIGATION, 1986, 4 (05) : 508 - 508
  • [24] Doxifluridine in patients with 5-FU resistant colorectal cancer
    Bajetta, E
    DiBartolomeo, M
    Somma, L
    Vicario, G
    Celio, L
    Bignami, P
    Bandieri, E
    Baldini, M
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 705 - 705
  • [25] Methotrexate (MTX) and 5-fluorouracil (5-FU) in advanced colorectal cancer patients previously treated with adjuvant 5-FU
    Pronzato, P
    Vaira, F
    Viganni, A
    Losardo, P
    Bertelli, G
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 760 - 760
  • [26] 5-FLUOROURACIL (5-FU) COMBINED WITH LEUCOVORIN (LV) IN PATIENTS WITH ADVANCED 5-FU RESISTANT COLORECTAL-CANCER
    VANGROENINGEN, CJ
    PETERS, GJ
    PINEDO, HM
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 : 202 - 202
  • [27] To 5-FU or not to 5-FU? When, how and why to use the new active agents in advanced colorectal cancer
    Cvitkovic, E
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1296 - 1296
  • [28] BET inhibitor bromosporine enhances 5-FU effect in colorectal cancer cells
    Cheng, Xueyuan
    Huang, Zhong
    Long, Di
    Jin, Wei
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2020, 521 (04) : 840 - 845
  • [29] Synthesis and Chemopreventive Potential of 5-FU/Genistein Hybrids on Colorectal Cancer Cells
    Moreno-Quintero, Gustavo
    Castrillon-Lopez, Wilson
    Herrera-Ramirez, Angie
    Yepes-Perez, Andres F.
    Quintero-Saumeth, Jorge
    Cardona-Galeano, Wilson
    PHARMACEUTICALS, 2022, 15 (10)
  • [30] Andrographolide reversed 5-FU resistance in human colorectal cancer by elevating BAX expression
    Wang, Weicheng
    Guo, Wenjie
    Li, Lele
    Fu, Zan
    Liu, Wen
    Gao, Jian
    Shu, Yongqian
    Xu, Qiang
    Sun, Yang
    Gu, Yanhong
    BIOCHEMICAL PHARMACOLOGY, 2016, 121 : 8 - 17